National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer—Is Active Surveillance Appropriate?

Purpose: We compared pathological and biochemical outcomes after radical prostatectomy in patients at favorable intermediate risk who fulfilled current NCCN® (National Comprehensive Cancer Network®) Guidelines® for active surveillance criteria to outcomes in patients who met more traditional criteria for active surveillance. Materials and Methods: We queried our institutional review board approved prostate cancer database for patients who met NCCN criteria for very low risk (T1c, Grade Group 1, 3 or fewer of 12 cores, 50% or less core volume and prostate specific antigen density less than 0.15 ng/ml), low risk (T1‐T2a, Grade Group 1 and prostate specific antigen less than 10 ng/ml) or favorable intermediate risk (major pattern grade 3 and less than 50% positive biopsy cores) and who had 1 intermediate risk factor, including T2b/c, Grade Group 2 or prostate specific antigen 10 to 20 ng/ml. Men at intermediate risk who did not meet favorable criteria were labeled as being at unfavorable intermediate risk. Patients at favorable intermediate risk were compared to those at very low and low risk, and those at unfavorable intermediate risk to identify differences in rates of adverse pathological findings at radical prostatectomy, including Gleason score Grade Group 3–5, nonorgan confined disease or nodal involvement. Time to biochemical recurrence was compared among the groups using Cox regression. Results: A total of 3,686 patients underwent radical prostatectomy between January 1, 2014 and December 31, 2015. Of these men 1,454, 250 and 1,362 fulfilled the criteria for low, favorable intermediate and unfavorable intermediate risk, respectively. The rate of adverse pathological findings in favorable intermediate risk cases was significantly higher than in low risk cases and significantly lower than in unfavorable intermediate risk cases (27.4% vs 14.8% and 48.5%, respectively, each p <0.001). Time to biochemical recurrence differed significantly among the risk groups (p <0.001). Conclusions: Relative to men at low risk those at favorable intermediate risk represent a distinct group. Care should be taken when selecting these patients for active surveillance and monitoring them once they are in an active surveillance program.

[1]  Mufaddal Mamawala,et al.  Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ronald C. Chen,et al.  Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[4]  H. G. van der Poel,et al.  Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. , 2015, Urologic oncology.

[5]  Y. Yamada,et al.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. , 2013, European urology.

[6]  Liying Zhang,et al.  Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. , 2016, The Journal of urology.

[7]  J. Epstein,et al.  Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group , 2018, JAMA Oncology.

[8]  Kirsten L. Greene,et al.  The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. , 2011, The Journal of urology.

[9]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[10]  P. Carroll,et al.  Active surveillance for prostate cancer: a narrative review of clinical guidelines , 2016, Nature Reviews Urology.

[11]  A. Costello,et al.  Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort , 2016, BJU international.

[12]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Siemens Radical prostatectomy or watchful waiting in early prostate cancer? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  P. Maté Mate [Radical prostatectomy versus observation for localized prostate cancer]. , 2013, Revista clinica espanola.

[15]  M. Roobol,et al.  A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. , 2016, European urology.

[16]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[17]  Rodolfo Montironi,et al.  The contemporary concept of significant versus insignificant prostate cancer , 2011 .

[18]  A. Evans,et al.  Active surveillance for the management of localized prostate cancer: Guideline recommendations. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[19]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[20]  Robert J Volk,et al.  Physician variation in management of low-risk prostate cancer: a population-based cohort study. , 2014, JAMA internal medicine.

[21]  T. Tammela,et al.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.

[22]  J. Hugosson,et al.  Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. , 2016, European urology.

[23]  M. Soloway,et al.  Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. , 2010, European urology.

[24]  David S. Yee,et al.  Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. , 2011, The Journal of urology.